Pittsburgh, PA, United States

University of Pittsburgh

www.pitt.edu
Pittsburgh, PA, United States

The University of Pittsburgh is a state-related research university located in Pittsburgh, Pennsylvania. It was founded on the edge of the American frontier as the Pittsburgh Academy in 1787, and evolved into the Western University of Pennsylvania by alteration of its charter in 1819. After surviving two devastating fires and various relocations within the area, the school moved to its current location in the Oakland neighborhood of the city and was renamed to the University of Pittsburgh in 1908. For most of its history Pitt was a private institution, until it became part of the Commonwealth System of Higher Education in 1966.The university is composed of 17 undergraduate and graduate schools and colleges located at its urban Pittsburgh campus, home to the university's central administration and 28,766 undergraduate, graduate, and professional students. The university also includes four additional undergraduate schools located at campuses within Western Pennsylvania: Bradford, Greensburg, Johnstown, and Titusville. The 132-acre Pittsburgh campus comprises multiple historic buildings of the Schenley Farms Historic District, most notably its 42-story gothic revival centerpiece, the Cathedral of Learning. The campus is situated adjacent to the flagship medical facilities of its closely affiliated University of Pittsburgh Medical Center , as well as the Carnegie Museums of Pittsburgh, Schenley Park, and Carnegie Mellon University.The university has an annual operating budget of approximately $2 billion that includes nearly $900 million in research and development expenditures. A member of the Association of American Universities, Pitt is the sixth largest recipient of federally sponsored research funding among U.S. universities in 2013 and is a major recipient of research funding from the National Institutes of Health. It is the second largest non-government employer in the Pittsburgh region behind UPMC. Pitt has been placed among the top public universities in the United States in both domestic and international rankings, and has been listed as a "best value" in higher education by multiple publications.Pitt students have access to various arts programs throughout the campus and city, and can participate in approximately 350 student organizations. Pitt's varsity athletic teams, collectively known as the Pittsburgh Panthers, compete in Division I of the NCAA, primarily as members of the Atlantic Coast Conference. Wikipedia.


Time filter

Source Type

Patent
University of Pittsburgh | Date: 2017-03-01

Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.


Patent
University of Pittsburgh | Date: 2017-02-14

A method of imaging a blood vessel includes delivering a bubble-based contrast agent within the vessel and positioning at least one ultrasound device in the vicinity of the bubble-based contrast agent within the vessel. A first burst of low-frequency ultrasound energy can be delivered to excite the bubble-based contrast agent into oscillation within the vessel, and a second burst of high-frequency ultrasound energy can be delivered at the excited bubble-based contrast agent. A return signal from the burst of high-frequency ultrasound energy can be received and processed to obtain one or more images.


Patent
University of Pittsburgh and Louisiana State University | Date: 2017-02-27

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fimgal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.


Patent
University of Pittsburgh | Date: 2017-03-08

A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.


Patent
University of Pittsburgh and Wake forest University | Date: 2017-02-10

The invention provides a method of diagnosing a disease or a predisposition to contract a disease by assaying for mutations of uromodulin (UMOD) within a test subject or patient. The presence of a mutation in the UMOD supports a diagnosis of a disease or a predisposition to contract a disease within the patient.


Patent
University of Pittsburgh | Date: 2017-03-20

The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. Influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.


Patent
University of Pittsburgh and Musc Foundation For Research Development | Date: 2017-04-27

A compound, or a pharmaceutically acceptable salt thereof, having a structure of


Patent
University of Pittsburgh | Date: 2017-08-02

Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.


Patent
University of Arkansas and University of Pittsburgh | Date: 2017-02-09

Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. The separatome-based protein expression and purification platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both. Moreover, the separatome-based protein expression and purification platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification. The separatome-based protein expression and purification platform is an efficient bioseparation system that intertwines host cell expression systems and chromatography.


The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.

Loading University of Pittsburgh collaborators
Loading University of Pittsburgh collaborators